CA2174133C - Use of alpha receptor antagonists for the treatment of chronic muscle pain - Google Patents

Use of alpha receptor antagonists for the treatment of chronic muscle pain Download PDF

Info

Publication number: CA2174133C
Authority: CA; Canada
Prior art keywords: pain; activity; emg; patients; treatment
Prior art date: 1993-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002174133A

Other languages

English (en)

French (fr)

Other versions

CA2174133A1 (en

Inventor

David R. Hubbard, Jr.

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MYOTECH Inc

Original Assignee

MYOTECH Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-14

Filing date

1994-10-14

Publication date

2007-09-18

1994-10-14 Application filed by MYOTECH Inc filed Critical MYOTECH Inc

1995-04-20 Publication of CA2174133A1 publication Critical patent/CA2174133A1/en

2007-09-18 Application granted granted Critical

2007-09-18 Publication of CA2174133C publication Critical patent/CA2174133C/en

2014-10-14 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 59
208000000112 Myalgia Diseases 0.000 title claims abstract description 38
208000013465 muscle pain Diseases 0.000 title claims abstract description 36
239000002464 receptor antagonist Substances 0.000 title claims abstract description 24
229940044551 receptor antagonist Drugs 0.000 title claims abstract description 24
230000001684 chronic effect Effects 0.000 title claims description 38
230000000694 effects Effects 0.000 claims abstract description 131
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims abstract description 31
229960003418 phenoxybenzamine Drugs 0.000 claims abstract description 27
229960001999 phentolamine Drugs 0.000 claims abstract description 25
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims abstract description 25
ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 claims abstract description 13
229960003602 guanethidine Drugs 0.000 claims abstract description 13
238000007918 intramuscular administration Methods 0.000 claims abstract description 6
238000002567 electromyography Methods 0.000 claims description 118
230000002232 neuromuscular Effects 0.000 claims description 51
230000005856 abnormality Effects 0.000 claims description 49
230000002269 spontaneous effect Effects 0.000 claims description 44
239000003814 drug Substances 0.000 claims description 17
230000002441 reversible effect Effects 0.000 claims description 8
230000001747 exhibiting effect Effects 0.000 claims description 5
230000002427 irreversible effect Effects 0.000 claims description 5
VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical group [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
229960003006 phenoxybenzamine hydrochloride Drugs 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims 1
238000000034 method Methods 0.000 abstract description 41
210000003205 muscle Anatomy 0.000 abstract description 32
238000003745 diagnosis Methods 0.000 abstract description 5
230000000903 blocking effect Effects 0.000 abstract description 3
208000005392 Spasm Diseases 0.000 abstract description 2
230000002159 abnormal effect Effects 0.000 abstract description 2
230000008700 sympathetic activation Effects 0.000 abstract description 2
230000001404 mediated effect Effects 0.000 abstract 1
208000002193 Pain Diseases 0.000 description 105
230000036407 pain Effects 0.000 description 90
238000002347 injection Methods 0.000 description 51
239000007924 injection Substances 0.000 description 51
230000002889 sympathetic effect Effects 0.000 description 39
239000003795 chemical substances by application Substances 0.000 description 32
239000005557 antagonist Substances 0.000 description 25
238000002559 palpation Methods 0.000 description 23
208000001640 Fibromyalgia Diseases 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
230000004044 response Effects 0.000 description 17
206010019233 Headaches Diseases 0.000 description 15
208000000094 Chronic Pain Diseases 0.000 description 13
231100000869 headache Toxicity 0.000 description 13
208000011580 syndromic disease Diseases 0.000 description 12
239000000203 mixture Substances 0.000 description 11
238000011084 recovery Methods 0.000 description 11
239000000674 adrenergic antagonist Substances 0.000 description 10
230000004064 dysfunction Effects 0.000 description 10
208000008035 Back Pain Diseases 0.000 description 9
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 9
229940079593 drug Drugs 0.000 description 9
229960004194 lidocaine Drugs 0.000 description 9
230000009467 reduction Effects 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
238000012360 testing method Methods 0.000 description 9
208000008548 Tension-Type Headache Diseases 0.000 description 8
238000012216 screening Methods 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
230000000007 visual effect Effects 0.000 description 8
208000008930 Low Back Pain Diseases 0.000 description 7
208000030858 Myofascial Pain Syndromes Diseases 0.000 description 7
206010043269 Tension headache Diseases 0.000 description 7
210000001087 myotubule Anatomy 0.000 description 7
230000008925 spontaneous activity Effects 0.000 description 7
241000219061 Rheum Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
230000002567 autonomic effect Effects 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000002411 adverse Effects 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
229940087490 dibenzyline Drugs 0.000 description 4
208000002173 dizziness Diseases 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000000835 fiber Substances 0.000 description 4
210000003811 finger Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000030214 innervation Effects 0.000 description 4
239000003589 local anesthetic agent Substances 0.000 description 4
230000005923 long-lasting effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000003340 mental effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 3
208000008454 Hyperhidrosis Diseases 0.000 description 3
206010028836 Neck pain Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000002160 alpha blocker Substances 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
229960003150 bupivacaine Drugs 0.000 description 3
238000003759 clinical diagnosis Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000008602 contraction Effects 0.000 description 3
230000036461 convulsion Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000007794 irritation Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000004699 muscle spindle Anatomy 0.000 description 3
108091008709 muscle spindles Proteins 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000002123 temporal effect Effects 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010003272 Hyaluronate lyase Proteins 0.000 description 2
102000001974 Hyaluronidases Human genes 0.000 description 2
206010049816 Muscle tightness Diseases 0.000 description 2
206010028391 Musculoskeletal Pain Diseases 0.000 description 2
206010031127 Orthostatic hypotension Diseases 0.000 description 2
208000028911 Temporomandibular Joint disease Diseases 0.000 description 2
206010043220 Temporomandibular joint syndrome Diseases 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
238000011221 initial treatment Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000003447 ipsilateral effect Effects 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
208000013433 lightheadedness Diseases 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
208000015004 muscle tenderness Diseases 0.000 description 2
230000008035 nerve activity Effects 0.000 description 2
208000018360 neuromuscular disease Diseases 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
230000007170 pathology Effects 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
229960004919 procaine Drugs 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
208000000029 referred pain Diseases 0.000 description 2
230000035807 sensation Effects 0.000 description 2
230000035900 sweating Effects 0.000 description 2
238000012353 t test Methods 0.000 description 2
210000003813 thumb Anatomy 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
206010016326 Feeling cold Diseases 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000027109 Headache disease Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000018650 Intervertebral disc disease Diseases 0.000 description 1
NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010050031 Muscle strain Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
208000007613 Shoulder Pain Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000037007 arousal Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
230000007211 cardiovascular event Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002192 cholecystectomy Methods 0.000 description 1
208000022371 chronic pain syndrome Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
208000013219 diaphoresis Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960001389 doxazosin Drugs 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940124645 emergency medicine Drugs 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000008029 eradication Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
238000010304 firing Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
HPBNRIOWIXYZFK-UHFFFAOYSA-N guanadrel Chemical compound O1C(CNC(=N)N)COC11CCCCC1 HPBNRIOWIXYZFK-UHFFFAOYSA-N 0.000 description 1
229960003845 guanadrel Drugs 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960002056 indoramin Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
229960001980 metirosine Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
230000004220 muscle function Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
230000000272 proprioceptive effect Effects 0.000 description 1
201000003004 ptosis Diseases 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
-1 terzosin Chemical compound 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229960002312 tolazoline Drugs 0.000 description 1
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
229960002906 trimazosin Drugs 0.000 description 1
YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002174133A 1993-10-14 1994-10-14 Use of alpha receptor antagonists for the treatment of chronic muscle pain Expired - Fee Related CA2174133C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/138,453 US5513661A (en)	1993-10-14	1993-10-14	Use of sympathetic blockade for treatment of chronic muscle pain
US08/138,453		1993-10-14
PCT/US1994/011615 WO1995010275A1 (en)	1993-10-14	1994-10-14	Use of alpha receptor antagonists for the treatment of chronic muscle pain

Publications (2)

Publication Number	Publication Date
CA2174133A1 CA2174133A1 (en)	1995-04-20
CA2174133C true CA2174133C (en)	2007-09-18

Family

ID=22482079

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002174133A Expired - Fee Related CA2174133C (en)	1993-10-14	1994-10-14	Use of alpha receptor antagonists for the treatment of chronic muscle pain

Country Status (6)

Country	Link
US (1)	US5513661A (de)
EP (1)	EP0723443B1 (de)
AT (1)	ATE270887T1 (de)
CA (1)	CA2174133C (de)
DE (1)	DE69433898T2 (de)
WO (1)	WO1995010275A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6009875A (en) *	1993-10-14	2000-01-04	Berlex Laboratories, Inc.	Use of sympathetic antagonists for treatment of chronic muscle pain
EP0850054A4 (de) *	1995-08-29	2000-09-13	New York Medical College	Formulierungen von haloalkylaminen mit lokalanästhetika und verfahren zur behandlung der reflexsympatischen dystrophie
ES2142703B1 (es) *	1996-07-09	2001-01-01	Univ Oviedo	Farmacos inhibidores de calmodulina para su uso como analgesicos.
JP3908281B2 (ja) *	1996-11-20	2007-04-25	マイオテック・インコーポレイテッド	筋肉の損傷や痛みの診断および治療に使用する、複数電極およびニードル注射装置
US6356783B1 (en)	1997-11-20	2002-03-12	David R. Hubbard, Jr.	Multi-electrode and needle injection device for diagnosis and treatment of muscle injury and pain
US7462618B2 (en) *	2003-08-27	2008-12-09	Sun Health Research Institute	Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists
US20090036799A1 (en) *	2007-03-30	2009-02-05	Medtronic Spinal And Biologics Business	Methods and Systems For The Diagnosis and Treatment of Medical Conditions in the Spine and Other Body Parts
WO2015035308A2 (en)	2013-09-06	2015-03-12	The University Of Montana	Method of reducing neuronal cell death with haloalkylamines
RU2680894C1 (ru) *	2018-02-27	2019-02-28	Людмила Николаевна Белимова	Способ лечения пациентов с головной болью напряжения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4525359A (en) *	1982-12-10	1985-06-25	Greenway Frank L Iii	Treatment for selective weight control
US5070084A (en) *	1990-02-26	1991-12-03	Campbell James N	Treatment of sympathetically maintained pain
CA2104873C (en) *	1991-02-26	2000-05-23	James N. Campbell	Compositions and methods of treatment of sympathetically maintained pain

1993
- 1993-10-14 US US08/138,453 patent/US5513661A/en not_active Expired - Fee Related
1994
- 1994-10-14 WO PCT/US1994/011615 patent/WO1995010275A1/en not_active Ceased
- 1994-10-14 EP EP94931355A patent/EP0723443B1/de not_active Expired - Lifetime
- 1994-10-14 CA CA002174133A patent/CA2174133C/en not_active Expired - Fee Related
- 1994-10-14 AT AT94931355T patent/ATE270887T1/de not_active IP Right Cessation
- 1994-10-14 DE DE69433898T patent/DE69433898T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1995010275A1 (en)	1995-04-20
US5513661A (en)	1996-05-07
CA2174133A1 (en)	1995-04-20
DE69433898D1 (de)	2004-08-19
DE69433898T2 (de)	2005-08-04
EP0723443B1 (de)	2004-07-14
EP0723443A1 (de)	1996-07-31
ATE270887T1 (de)	2004-07-15

Legal Events

Date	Code	Title	Description
2001-10-11	EEER	Examination request
2008-10-14	MKLA	Lapsed

Publication	Publication Date	Title
Light et al.	2009	Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder
Price et al.	1998	Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patients
Curatolo et al.	1997	Epidural epinephrine and clonidine: segmental analgesia and effects on different pain modalities
Sörensen et al.	1995	Pain analysis in patients with fibromyalgia: effects of intravenous morphine, lidocaine, and ketamine
Dellemijn et al.	1994	The interpretation of pain relief and sensory changes following sympathetic blockade
Jampel et al.	1988	Apraclonidine: a one-week dose-response study
US6009875A (en)	2000-01-04	Use of sympathetic antagonists for treatment of chronic muscle pain
KR102649644B1 (ko)	2024-03-21	편두통 예방을 위한 라스미디탄의 만성 야간 투여
EP0517850B1 (de)	2003-11-12	Zusammensetzungen und behandlungsverfahren für sympathisch unterhaltenen schmerz
CA2174133C (en)	2007-09-18	Use of alpha receptor antagonists for the treatment of chronic muscle pain
US4555397A (en)	1985-11-26	Method for anti-cholinergic blockage of withdrawal symptoms in smoking cessation
Patil et al.	2012	Is clonidine an adequate alternative to epinephrine as a vasoconstrictor in patients with hypertension?
Watso et al.	2022	Low-dose morphine reduces pain perception and blood pressure, but not muscle sympathetic outflow, responses during the cold pressor test
Wright	1994	Review of the symptomatic treatment of diabetic neuropathy
Theodorakis et al.	1993	The effectiveness of β-blockade and its influence on heart rate variability in vasovagal patients
Chou et al.	2023	Beta-blocker carteolol and oxprenolol produce cutaneous analgesia in response to needle pinpricks in the rat
Kim et al.	2001	Complex regional pain syndrome (type I) after electrical injury: a case report of treatment with continuous epidural block
US20020156101A1 (en)	2002-10-24	Use for pain management
Graves et al.	2001	The impact of nalmefene on side effects due to intrathecal morphine at cesarean section
Yilmaz	2019	Anesthesia Management for Carotid Endarterectomy
ARKIN et al.	1950	Tetraethylammonium chloride in the treatment of multiple sclerosis
Bruehl et al.	2010	Chronic pain-related changes in endogenous opioid analgesia: a case report
Sharma et al.	2009	Clinical and electromyographic deep tendon reflexes in polyneuropathy: diagnostic value and prevalence
Haxhiu et al.	1998	I1-imidazoline receptors and cholinergic outflow to the airways
Danchin et al.	1991	Comparative effects of oral molsidomine and nifedipine on methylergometrine-induced coronary artery spasm